Overview: Anti-Liver/Kidney Microsomal (LKM-1) IgA Antibody Rapid TestIntroduction: The Anti-Liver/Kidney Microsomal (LKM-1) IgA Antibody Rapid Test is a diagnostic tool designed to detect LKM-1 IgA antibodies in serum, whole blood, or saliva samples, facilitating the screening of autoimmune hepatitis. Associated with chronic liver inflammation, this autoimmune condition presents with jaundice, fatigue, and severe complications like cirrhosis if untreated, particularly in younger females or those with other autoimmune diseases. Per the 2023 American Association for the Study of Liver Diseases guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in hepatology clinics. This rapid diagnostic falls under immunology and targets individuals with liver symptoms, addressing the challenge of early detection to guide immunosuppressive therapy like prednisone. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing liver failure. Its multi-sample capability enhances its utility.Other Names: LKM-1 IgA Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Inova Diagnostics, this test advanced autoimmune hepatitis detection, providing a rapid alternative to immunofluorescence with a focus on IgA.Purpose: The test screens for LKM-1 IgA to guide autoimmune hepatitis diagnosis, assess liver damage, and inform treatment and prevention strategies.Test Parameters: Presence of LKM-1 IgA Antibody, detected with reasonable specificity to indicate autoimmune activity, typically detectable in serum or blood during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, fatigue, or family history of liver disease.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on jaundice, fatigue, abdominal pain, or prior liver disease diagnosis, as well as any family history of autoimmune diseases or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune hepatitis including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent liver injury can affect results. Correlation with liver biopsy or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible autoimmune hepatitis, necessitating further investigation like liver biopsy or hepatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Hepatologists should be consulted for case management, treatment planning, and coordination with liver disease programs.Additional Supporting Tests: Liver biopsy, ANA, or SMA for confirmation.Test Limitations: The test may produce false positives in other autoimmune conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AASLD Guidelines 2023, Hepatology 2024, Immunology 2025.